Anti-obesity agent and use thereof

Abstract

Disclosed is a novel anti-obesity agent. Also disclosed is a therapeutic method using the anti-obesity agent. The anti-obesity agent comprises a GABAB receptor agonist or a pharmacologically acceptable salt thereof as an active ingredient.

Description

technical field [0001] The present invention relates to an anti-obesity drug, a treatment method for obesity and the like. Background technique [0002] In 1994, the pathogenic gene of the ob / ob mouse, a model animal of obesity and diabetes, was identified, thus showing that leptin deficiency is the cause of obesity and diabetes (Non-Patent Document 1). Leptin secreted from adipocytes acts on the arcuate nucleus of the hypothalamus as the primary center of feeding regulation, suppresses the expression of the hyperphagia peptide neuropeptide Y (NPY) expressed in the arcuate nucleus, and enhances α-MSH as an inhibitory peptide of feeding Expression of precursor proopiomelanocortin (POMC), thereby regulating energy balance in a negative direction (Non-Patent Documents 2, 3). However, the blood leptin concentration is generally high in obese persons, and sufficient anti-obesity effects have not been observed by administering leptin to obese persons (Non-Patent Documents 4 and 5...

AI Technical Summary

Problems solved by technology

[0003] As the main anti-obesity drugs currently clinically used, there are brain norepinephrine reabsorption inhibitor mazindol, brain norepinephrine / serotonin reabsorption inhibitor sibutramine, cannabinoid receptor Rimonabant, a selective antagonist of body 1, etc., neither drug has the effect of inhibiting NPY or enhancing POMC

On the other hand, it has been revealed that ciliary neurotrophic factor (CNTF) exhibits anti-obesity effects through the same signal transduction system as leptin, and its clinical application is currently being developed. Antibodies become a problem (Non-Patent Document 6)

Images